New Clinical Developments and Advanced Clinical Studies Offer Superior Treatment Options - Research Report on Alnylam, Immunomedics, Tesaro, InterMune and Synta
Editor Note: For more information about this release, please scroll to bottom.
Jun 27, 2013, 08:00 ET
NEW YORK, June 27, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Immunomedics Inc. (NASDAQ: IMMU), Tesaro, Inc. (NASDAQ: TSRO), InterMune Inc. (NASDAQ: ITMN) and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Alnylam Pharmaceuticals, Inc. Research Report
On June 20, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it presented pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5, at the 6th International Conference on Complement Therapeutics, which was held from June 18 to June 23, 2013 in Greece. The presentation, "Development of an RNAi Therapeutic Silencing the C5 Component of Complement," showed the potent, dose-dependent, and durable RNAi-mediated knockdown of serum C5 and inhibition of complement-mediated hemolytic activity of approximately 90% with a subcutaneously administered RNAi therapeutic. "C5 is a genetically and clinically validated target that exemplifies the potential of Alnylam's '5x15' product strategy for innovative new medicines. First, C5 is predominantly expressed in liver, where we have established clinical activity and tolerability for RNAi therapeutics. In addition, our clinical development plan for an RNAi therapeutic targeting C5 will be facilitated by serum biomarkers in Phase I trials and a relatively streamlined and focused path for advanced development," said Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development at Alnylam. The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5328_ALNY]
Immunomedics Inc. Research Report
On June 13, 2013, Immunomedics Inc. (Immunomedics) announced that UCB reported new data from an open-label extension of the EMBLEM phase 2b study evaluating the long-term effects of epratuzumab treatment in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). "In EMBLEM, a dose-ranging, phase 2b study, reduction in disease activity was observed in patients treated with epratuzumab," said Professor Daniel J Wallace MD, Clinical Professor of Medicine, Cedars-Sinai Medical Center, California, US. He added, "This double-blind study had a relatively short 12-week, placebo-controlled, treatment period and it was important to accumulate long-term data on epratuzumab in the treatment of SLE. The phase 2b extension study adds new two year open-label data on epratuzumab to that already available from the 12-week, randomized, controlled study." The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/cc0f_IMMU]
Tesaro, Inc. Research Report
On June 4, 2013, TESARO Inc. (Tesaro) announced the final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP). Tesaro reported that at a dose of 300 milligrams once daily, 75% with platinum sensitive high grade serous ovarian cancer achieved a RECIST response, and across all dose levels (30 milligrams to 400 milligrams daily), a RECIST response rate of 46% was observed within this population. Also, a RECIST response rate of 50% was achieved in patients with platinum sensitive ovarian cancer and germline BRCA mutations. Dr. Mary Lynne Hedley, President of TESARO commented, "The results of this study provide further support for the design of our planned Phase 3 trials in ovarian and breast cancer and, in particular, the potential utility of platinum sensitivity and BRCA status as predictors of response to niraparib." The Full Research Report on Tesaro, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4f59_TSRO]
InterMune Inc. Research Report
On June 14, 2013, InterMune, Inc. (InterMune) announced that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal of the government of Italy. Esbriet is InterMune's product for the treatment of adult patients with mild to moderate idiopathic pulmonary fibrosis (IPF). Giacomo Di Nepi, Executive Vice President and Managing Director, Europe for InterMune, said, "We are very pleased to see the publication of our pricing and reimbursement agreement, which allows us to make Esbriet available very soon to Italian patients with mild to moderate IPF. Our entire organization is prepared to launch Esbriet in Italy and our Italian team is excited and fully committed to making Esbriet available to all appropriate IPF patients as rapidly as possible." The Full Research Report on InterMune Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/d68f_ITMN]
Synta Pharmaceuticals Corp. Research Report
On June 3, 2013, Synta Pharmaceuticals Corp. (Synta) announced the results from an interim survival analysis of the GALAXY-1 TRIAL, a study designed to evaluate the efficacy and safety of the Company's lead drug candidate, the Hsp90 inhibitor ganetespib, as second-line treatment for patients with advanced non-small cell lung adenocarcinoma. The results show that the combination of ganetespib plus docetaxel improves overall survival and progression-free-survival compared to docetaxel alone. "Outside of certain genetically-defined patient populations, there have been no new options for the treatment of patients with non-small cell adenocarcinoma following first-line therapy in nearly a decade," said Dr. Dean A. Fennell, University Hospital, Leicester, UK, co-Principal Investigator of GALAXY-1. He further added, "The magnitude and consistency of the activity reported today are very encouraging and bode well for the outcome of the GALAXY-2 Phase 3 study." The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/8ec0_SNTA]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Wall Street Reports
Share this article